1h Free Analyst Time
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Retinoic acid receptor alpha (RARA) is a nuclear receptor that is encoded by the RARA gene. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. It promotes the survival and development of early meiotic prophase spermatocytes. It regulates expression of target genes in a ligand-dependent manner by recruiting chromatin complexes containing KMT2E/MLL5 and mediates retinoic acid-induced granulopoiesis.Speak directly to the analyst to clarify any post sales queries you may have.
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1, 5 and 3 respectively. Report covers products from therapy areas Dermatology, Oncology, Immunology, Ophthalmology, Respiratory, Central Nervous System, Gastrointestinal, Genetic Disorders, Hematological Disorders, Infectious Disease, Male Health and Metabolic Disorders which include indications Acne Vulgaris, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, Bronchopulmonary Dysplasia, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type A, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type B, Batten Disease, Germ Cell Tumors, Hand Dermatitis, Inflammatory Bowel Disease, Kaposi Sarcoma, Male Contraception, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Neutropenia, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Retinopathy Of Prematurity, Sarcomas, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).
The latest report Retinoic Acid Receptor Alpha - Drugs In Development, 2022, outlays comprehensive information on the Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)
- The report reviews Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Overview
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Companies Involved in Therapeutics Development
- Advent Therapeutics Inc
- Avecho Biotechnology Ltd
- Galephar Pharmaceutical Research Inc
- Io Therapeutics Inc
- Novartis AG
- Orphagen Pharmaceuticals Inc
- Orphanix GmbH
- Ortho Dermatologics Inc
- Polaryx Therapeutics Inc
- Selphagy Therapeutics Inc
- Sunny BioDiscovery Inc
- TherapyX Inc
- Toko Pharmaceutical Industries Co Ltd
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Drug Profiles
- Product Description
- Mechanism Of Action
- History of Events
- Product Description
- Mechanism Of Action
- History of Events
- Product Description
- Mechanism Of Action
- History of Events
- alitretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- alitretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IRX-5183 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OR-812 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SBD-073 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Agonize RAR Alpha and RXR Alpha for Acute Promyelocytic Leukemia - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Antagonize RAR Alpha for Opthamology - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tamibarotene - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tazarotene - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- vitamin A palmitate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- vitamin A palmitate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Dormant Products
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Discontinued Products
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Product Development Milestones
- Featured News & Press Releases
- Aug 03, 2022: Syros receives positive opinion on orphan drug designation from the European Medicines Agency for tamibarotene for the treatment of MDS
- Feb 02, 2022: Syros receives FDA Orphan Drug Designation for tamibarotene for the treatment of MDS
- Oct 28, 2021: The first and only tazarotene lotion indicated for acne vulgaris in patients 10 years of age and older, ARAZLO now available for patients by prescription across Canada
- Oct 19, 2021: Ortho Dermatologics to present new data on ARAZLO at the 2021 Fall Clinical Dermatology Conference
- Sep 10, 2021: RaQualia announces milestone payment from Syros
- Sep 09, 2021: Syros announces first patient dosed in SELECT-AML-1 trial of Tamibarotene in combination with Venetoclax and Azacitidine in newly diagnosed unfit AML
- Aug 04, 2021: Health Canada approves ARAZLO (Tazarotene) Lotion, 0.045%, first such lotion treatment for acne vulgaris
- Apr 21, 2021: Ortho Dermatologics to present abstract on ARAZLO (tazarotene) Lotion at 2021 American Academy of Dermatology Annual Meeting
- Dec 05, 2020: Syros presents new data from Phase 2 clinical trial of SY-1425 and announces plans to initiate registration-enabling trial in MDS and randomized Phase 2 trial in AML
- Nov 04, 2020: Syros to present new data from phase 2 clinical trial of SY-1425 in oral presentations at 62nd ASH annual meeting
- Jul 23, 2020: Ortho Dermatologics launches ARAZLO (tazarotene) lotion, 0.045%, in the United States
- Jun 23, 2020: Ortho Dermatologics launches ARAZLO (tazarotene) lotion, 0.045%, in the United States
- Jan 13, 2020: Ortho Dermatologics announces publication of pivotal phase 3 data on ARAZLO (tazarotene) Lotion, 0.045% in the Journal of Drugs in Dermatology (JDD)
- Jan 12, 2020: Syros announces new update on SY-1425
- Dec 19, 2019: FDA approves Ortho Dermatologics' ARAZLO (Tazarotene) lotion, 0.045%, for acne vulgaris
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Advent Therapeutics Inc, 2022
- Pipeline by Avecho Biotechnology Ltd, 2022
- Pipeline by Galephar Pharmaceutical Research Inc, 2022
- Pipeline by Io Therapeutics Inc, 2022
- Pipeline by Novartis AG, 2022
- Pipeline by Orphagen Pharmaceuticals Inc, 2022
- Pipeline by Orphanix GmbH, 2022
- Pipeline by Ortho Dermatologics Inc, 2022
- Pipeline by Polaryx Therapeutics Inc, 2022
- Pipeline by Selphagy Therapeutics Inc, 2022
- Pipeline by Sunny BioDiscovery Inc, 2022
- Pipeline by TherapyX Inc, 2022
- Pipeline by Toko Pharmaceutical Industries Co Ltd, 2022
- Dormant Products, 2022
- Dormant Products, 2022 (Contd..1)
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Advent Therapeutics Inc
- Avecho Biotechnology Ltd
- Galephar Pharmaceutical Research Inc
- Io Therapeutics Inc
- Novartis AG
- Orphagen Pharmaceuticals Inc
- Orphanix GmbH
- Ortho Dermatologics Inc
- Polaryx Therapeutics Inc
- Selphagy Therapeutics Inc
- Sunny BioDiscovery Inc
- TherapyX Inc
- Toko Pharmaceutical Industries Co Ltd
